Möchten Sie immer auf dem neuesten Stand bleiben?

FILING OF ANNUAL REPORT ON FORM 20-F WITH THE US SECURITIES AND EXCHANGE COMMISSION AstraZeneca PLC (the Company) announced today that it filed its Annual Report on Form 20-F with the US Securities...

ANNUAL FINANCIAL REPORT AstraZeneca PLC (the Company) announced today the publication of its Annual Report and Form 20-F Information 2015 (Annual Report). A copy of the Annual Report will be...

ASTRAZENECA REPORTS TOP-LINE RESULT OF TREMELIMUMAB MONOTHERAPY TRIAL IN MESOTHELIOMA Trial did not meet primary endpoint of improving overall survival in challenging to treat mesothelioma patients...

ASTRAZENECA ENTERS LICENSING AGREEMENT WITH CHINA MEDICAL SYSTEM HOLDINGS FOR HYPERTENSION MEDICINE Agreement for Plendil in China reinforces AstraZeneca's focus on...

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 25 February 2016, the interest of Mr Pascal Soriot, a person discharging managerial responsibilities, in...

Acalabrutinib RecommendEd for Orphan Drug Designation IN EUROPE for THREE indications AstraZeneca and Acerta Pharma BV, a company in which AstraZeneca has a majority equity investment, today...

Approval of new 60mg dose expands current indication to include long-term treatment beyond the first year AstraZeneca today announced that the European Commission has granted marketing authorisation...

AstraZeneca today announced that the European Commission (EC) has granted marketing authorisation for ZurampicTM(lesinurad) 200mg in combination with a xanthine oxidase inhibitor (XOI) for the...

DURVALUMAB granted Breakthrough Therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer AstraZeneca and MedImmune, its global biologics research and...

AstraZeneca PLC Listing Rule LR 9.6.14 R (2) On 16 February 2016, Leif Johansson, Non-Executive Chairman of AstraZeneca PLC, was elected as a new member to the Board of Directors of Autoliv, Inc. A...